CA
IHE icon

CoreCap Advisors’s iShares US Pharmaceuticals ETF IHE Stock Holding History

CoreCap Advisors’s Portfolio IHE Stock Details IHE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-100
Closed -$6.55K – 2868
2025
Q2 		$6.55K Buy
+100
New +$6.51K ﹤0.01% 2035

Other funds holding IHE

Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

CoreCap Advisors's IHE Position: Q3 2025 in Review

CoreCap Advisors sold out of iShares US Pharmaceuticals ETF (IHE) in Q3 2025, closing a stake of 100 shares — an estimated $6.55K sold.

CoreCap Advisors first reported a position in IHE in Q2 2025 and held it in 1 quarter. The position peaked at $6.55K in Q2 2025. 149 funds tracked by Wall St. Rank hold IHE as of Q3 2025.

  • CoreCap Advisors reported no remaining iShares US Pharmaceuticals ETF position as of Q3 2025 after selling out during the quarter.
  • CoreCap Advisors sold 100 iShares US Pharmaceuticals ETF shares in Q3 2025, an estimated $6.55K.
  • CoreCap Advisors first reported a position in iShares US Pharmaceuticals ETF in Q2 2025 and held it in 1 quarter.
  • CoreCap Advisors's iShares US Pharmaceuticals ETF position peaked at $6.55K in Q2 2025.
  • 149 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q3 2025.

Based on CoreCap Advisors's 13F filing for Q3 2025, filed 22 Oct 2025.